FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3097057724> ?p ?o ?g. }

• W3097057724 endingPage "33" @default.
• W3097057724 startingPage "32" @default.
• W3097057724 abstract "Background Treatment with chimeric antigen receptor (CAR) T cell therapies have shown dramatic, often durable responses for relapsed/refractory B-cell malignancies. However, it can be associated with significant side effects such as cytokine release syndrome (CRS), immune effector-cell associated neurotoxicity syndrome (ICANS) and life-threatening consumptive coagulopathies. The underlying pathobiology of such hemostatic defects and their distinct clinical sequelae remains obscure. This retrospective study aims at quantifying CAR T therapy associated bleeding and thrombotic complications and their association with CRS, ICANS, and laboratory derangements. Methods 130 adult patients with DLBCL or B-ALL treated between 2017-2020 with CD19 CAR-T therapy axicabtagene ciloleucel (N=90) or a bispecific CD 19/22 CAR construct utilizing 4-1BB costimulatory domains (N=40) were analyzed to determine dynamics of coagulation parameters and platelet counts as well as incidences of bleeding or thrombosis in the first three months after CAR T infusion. Events were included if graded ≥ 2 or if intervention was required. Platelet counts and coagulation parameters were collected prior to lymphodepletion (pre-LD), day 0, 3, 7, 14, 21, 28, 60 and 90. Results 12 (9.2%) and 8 (6.2%) patients developed bleeding and thrombotic complications in the first three months after CAR-T infusion, respectively. Events are characterized in Figure 1. All bleeding events occurred between days 0-30 (median 17.5, range 8-30), while thrombotic events occurred between days 2-91 (median day 29, range, 2-91). Two (1.5%) patients experienced both bleeding and thrombosis. Bleeding events coincided with the onset of thrombocytopenia and hypofibrinogenemia, and patients who bled had lower platelet (median 22.5 vs. 47 K/uL; p=0.03) and fibrinogen (median 151 vs. 351 ug/mL; p=0.007) nadirs in the first 30 days compared to those without bleeding. Temporally, the lowest median platelet nadir occurred at day 7 in patients with bleeding events vs. day 21 in patients without bleeding, while timing of fibrinogen nadirs were at day 21 in both. Patients with bleeding episodes were more likely to be older (median age: 70 vs. 60 yrs, p=0.03), have thrombocytopenia prior to lymphodepletion therapy (median 117.5 vs. 174.5 K/uL, p=0.01), and have elevated LDH (lymphoma subgroup; p=0.07). Other lab derangements in the first 30 days seen more frequently in patients with bleeding included prolonged thrombin time (TT) (21% vs. 6%; p=0.02), PT (16% vs. 5%; p=0.06), and elevated d-dimer (16% vs. 3%; p=0.01) indicative of a consumptive process. Thrombotic events were not significantly associated with elevated or peak d-dimer values (median 4.97 vs. 2.37 ug/mL, p=0.20). Interestingly, occurrence or severity of CRS was not associated with bleeding or thrombotic events, nor was it associated with marked derangements in coagulation abnormalities. However, higher grade ICANS (grade &gt; 3) was associated with bleeding (42% vs. 15%; p=0.038), thrombosis (50% vs. 16%; p=0.03), and evidence of endothelial activation including PT prolongation (78% vs. 35%; p&lt;0.001), hypofibrinogenemia (57% vs. 20%; p=0.001), and trend towards elevated d-dimer (70% vs. 46%; p=0.06). 13 (10%) patients received anticoagulation for prophylaxis or therapeutic indications that predated CAR T infusion. Four started anticoagulation secondarily for thrombotic events after CAR-T infusion, and one received tissue plasminogen activator (tPA) for an acute stroke. In this group, no patients developed bleeding complications from anticoagulation. Conclusion Both bleeding (9.2%), and thrombotic (6.2%) events are observed after CAR T cell therapy, with bleeding limited to the first month in our cohort. Notably, ICANS was uniquely associated with PT prolongation, hypofibrinogenemia, and increased fibrin degradation, in addition to both bleeding and thrombosis. These results suggest that a systemic coagulopathy coincides with high grade ICANS and whether these neurologic events truly represent sequelae of widespread vascular dysfunction warrants further investigation. Anticoagulation was safe in the patients whom it was indicated. Risk factors for bleeding and thrombotic complications should be studied prospectively to develop risk-assessment models and clinical guidelines for management of bleeding and thrombosis (including prophylaxis) during CAR T therapy. Disclosures Muffly: Adaptive: Research Funding; Servier: Research Funding; Amgen: Consultancy. Negrin:BioEclipse Therapeutics: Current equity holder in private company; Magenta Therapeutics: Consultancy, Current equity holder in publicly-traded company; KUUR Therapeutics: Consultancy; Biosource: Current equity holder in private company; Amgen: Consultancy; UpToDate: Honoraria. Shizuru:Jasper Therapeutics, Inc: Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees. Meyer:Orca Bio: Research Funding. Shiraz:Kite, a Gilead Company: Research Funding; ORCA BioSystems: Research Funding. Rezvani:Pharmacyclics: Research Funding. Mackall:Apricity Health: Consultancy, Current equity holder in private company; NeoImmune Tech: Consultancy; Nektar Therapeutics: Consultancy; Allogene: Current equity holder in publicly-traded company; BMS: Consultancy; Lyell Immunopharma: Consultancy, Current equity holder in private company. Miklos:Adaptive Biotech: Consultancy, Other: Travel support, Research Funding; Kite-Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Research Funding; Juno-Celgene-Bristol-Myers Squibb: Consultancy, Other: Travel support, Research Funding; Allogene Therapeutics Inc.: Research Funding; Novartis: Consultancy, Other: Travel support, Research Funding; Pharmacyclics: Consultancy, Other: Travel support, Patents & Royalties, Research Funding; Janssen: Consultancy, Other: Travel support; Miltenyi Biotec: Research Funding. Sidana:Janssen: Consultancy." @default.
• W3097057724 created "2020-11-09" @default.
• W3097057724 creator A5001397662 @default.
• W3097057724 creator A5003368910 @default.
• W3097057724 creator A5005492422 @default.
• W3097057724 creator A5007168644 @default.
• W3097057724 creator A5012405884 @default.
• W3097057724 creator A5012590130 @default.
• W3097057724 creator A5014659823 @default.
• W3097057724 creator A5017390274 @default.
• W3097057724 creator A5030780456 @default.
• W3097057724 creator A5038377091 @default.
• W3097057724 creator A5040662951 @default.
• W3097057724 creator A5040802391 @default.
• W3097057724 creator A5053002300 @default.
• W3097057724 creator A5054569926 @default.
• W3097057724 creator A5054770306 @default.
• W3097057724 creator A5055668736 @default.
• W3097057724 creator A5072539716 @default.
• W3097057724 creator A5081926380 @default.
• W3097057724 creator A5081960635 @default.
• W3097057724 creator A5087779758 @default.
• W3097057724 date "2020-11-05" @default.
• W3097057724 modified "2023-10-16" @default.
• W3097057724 title "Bleeding and Thrombosis Are Associated with Endothelial Dysfunction in CAR-T Cell Therapy and Are Increased in Patients Experiencing Neurologic Toxicity" @default.
• W3097057724 doi "https://doi.org/10.1182/blood-2020-142218" @default.
• W3097057724 hasPublicationYear "2020" @default.
• W3097057724 type Work @default.
• W3097057724 sameAs 3097057724 @default.
• W3097057724 citedByCount "4" @default.
• W3097057724 countsByYear W30970577242022 @default.
• W3097057724 countsByYear W30970577242023 @default.
• W3097057724 crossrefType "journal-article" @default.
• W3097057724 hasAuthorship W3097057724A5001397662 @default.
• W3097057724 hasAuthorship W3097057724A5003368910 @default.
• W3097057724 hasAuthorship W3097057724A5005492422 @default.
• W3097057724 hasAuthorship W3097057724A5007168644 @default.
• W3097057724 hasAuthorship W3097057724A5012405884 @default.
• W3097057724 hasAuthorship W3097057724A5012590130 @default.
• W3097057724 hasAuthorship W3097057724A5014659823 @default.
• W3097057724 hasAuthorship W3097057724A5017390274 @default.
• W3097057724 hasAuthorship W3097057724A5030780456 @default.
• W3097057724 hasAuthorship W3097057724A5038377091 @default.
• W3097057724 hasAuthorship W3097057724A5040662951 @default.
• W3097057724 hasAuthorship W3097057724A5040802391 @default.
• W3097057724 hasAuthorship W3097057724A5053002300 @default.
• W3097057724 hasAuthorship W3097057724A5054569926 @default.
• W3097057724 hasAuthorship W3097057724A5054770306 @default.
• W3097057724 hasAuthorship W3097057724A5055668736 @default.
• W3097057724 hasAuthorship W3097057724A5072539716 @default.
• W3097057724 hasAuthorship W3097057724A5081926380 @default.
• W3097057724 hasAuthorship W3097057724A5081960635 @default.
• W3097057724 hasAuthorship W3097057724A5087779758 @default.
• W3097057724 hasBestOaLocation W30970577241 @default.
• W3097057724 hasConcept C121608353 @default.
• W3097057724 hasConcept C126322002 @default.
• W3097057724 hasConcept C141071460 @default.
• W3097057724 hasConcept C2777701055 @default.
• W3097057724 hasConcept C2780850621 @default.
• W3097057724 hasConcept C2780868729 @default.
• W3097057724 hasConcept C3875195 @default.
• W3097057724 hasConcept C71924100 @default.
• W3097057724 hasConcept C89560881 @default.
• W3097057724 hasConcept C90924648 @default.
• W3097057724 hasConceptScore W3097057724C121608353 @default.
• W3097057724 hasConceptScore W3097057724C126322002 @default.
• W3097057724 hasConceptScore W3097057724C141071460 @default.
• W3097057724 hasConceptScore W3097057724C2777701055 @default.
• W3097057724 hasConceptScore W3097057724C2780850621 @default.
• W3097057724 hasConceptScore W3097057724C2780868729 @default.
• W3097057724 hasConceptScore W3097057724C3875195 @default.
• W3097057724 hasConceptScore W3097057724C71924100 @default.
• W3097057724 hasConceptScore W3097057724C89560881 @default.
• W3097057724 hasConceptScore W3097057724C90924648 @default.
• W3097057724 hasIssue "Supplement 1" @default.
• W3097057724 hasLocation W30970577241 @default.
• W3097057724 hasOpenAccess W3097057724 @default.
• W3097057724 hasPrimaryLocation W30970577241 @default.
• W3097057724 hasRelatedWork W13788639 @default.
• W3097057724 hasRelatedWork W1982913438 @default.
• W3097057724 hasRelatedWork W1998274488 @default.
• W3097057724 hasRelatedWork W2060315896 @default.
• W3097057724 hasRelatedWork W2082094685 @default.
• W3097057724 hasRelatedWork W2083197627 @default.
• W3097057724 hasRelatedWork W2418625451 @default.
• W3097057724 hasRelatedWork W3198306613 @default.
• W3097057724 hasRelatedWork W4242457046 @default.
• W3097057724 hasRelatedWork W53249031 @default.
• W3097057724 hasVolume "136" @default.
• W3097057724 isParatext "false" @default.
• W3097057724 isRetracted "false" @default.
• W3097057724 magId "3097057724" @default.
• W3097057724 workType "article" @default.